Table of contents
Expand All Topics
Renal biopsy
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of renal biopsy are prepared by our editorial team based on guidelines from the Kidney Health Australia (KHA 2019).
1
Diagnostic procedures
Patient positioning: as per KHA 2019 guidelines, consider using the supine anterolateral position for native renal biopsy in patients with obesity or respiratory difficulty.
C
Show 3 more
More topics in this section
Needle selection
Image guidance
Inpatient care
Post-biopsy monitoring: as per KHA 2019 guidelines, keep the patient in hospital following a renal biopsy for strict bed-rest with frequent observations for 6-24 hours. Offer a 6-8 hours period of observation with same day discharge in low-risk patients.
B
Show 5 more
More topics in this section
Management of post-biopsy bleeding
Patient education
Patient education, pre-biopsy
As per KHA 2019 guidelines:
Educate and inform patients and their carers about renal biopsies including reasons for its use, risks and complications, pre- and post-biopsy management with particular regard to psychological issues such as anxiety. Provide education and information in a format suited to their learning needs.
B
Consider following the process outlined below to establish methods of communication and interaction with patients undergoing renal biopsy, to adequately prepare them for the procedure and alleviate unnecessary anxiety throughout the process:
Situation
Guidance
Pre-biopsy
Establish a visit plan
Deliver information for self-management pre-/post-procedure
Conduct thorough consent process outlining risks and necessity for biopsy
Biopsy
Admission - explain expected schedule
Pre-procedure - explain restrictions/timing (moving, eating, voiding), contact caregiver
Recovery - check in with patient at expected time
Discharge - explain postprocedural care, notify caregiver
All - keep informed of delays, multidisciplinary communication to manage comorbid conditions
Post-biopsy
Deliver results as soon as possible
⁄
More topics in this section
Patient education (post-biopsy)
Preventative measures
Prevention of post-biopsy bleeding, discontinuation of antiplatelet and anticoagulant therapy: as per KHA 2019 guidelines, continue aspirin in patients with high cardiovascular risks, including patients with coronary stents (particularly within 3 months of bare metal stent or 12 months of drug-eluting stent insertion), symptomatic myocardial ischemia or peripheral vascular disease (including patients with a peripheral stent), or previous ischemic stroke.
B
Show 5 more
More topics in this section
Prevention of post-biopsy bleeding (desmopressin)